Brookline Capital Markets analyst Kumaraguru Raja reiterated a Buy rating on Celsion (CLSN) today and set a price target of $4.00. The company’s shares closed last Thursday at $2.17.
According to TipRanks.com, Raja is a 5-star analyst with an average return of 31.8% and a 54.1% success rate. Raja covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Arcturus Therapeutics, and Outlook Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celsion with a $4.00 average price target.
See today’s analyst top recommended stocks >>
Celsion’s market cap is currently $165.5M and has a P/E ratio of -3.10. The company has a Price to Book ratio of 52.55.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
